Related Experiment Videos
Inflammation and Alzheimer's disease pathogenesis
Abstract:
Appreciation of the role that inflammatory mediators play in Alzheimer's disease (AD) pathogenesis continues to be hampered by two related misconceptions. The first is that to be pathogenically significant a neurodegenerative mechanism must be primary. The second is that inflammation merely occurs to clear the detritis of already existent pathology. The present review addresses these issues by showing that 1) inflammatory molecules and mechanisms are uniquely present or significantly elevated in the AD brain, 2) inflammation may be a necessary component of AD pathogenesis, 3) inflammation may be sufficient to cause AD neurodegeneration, and 4) retrospective and direct clinical trials suggest a therapeutic benefit of conventional antiinflammatory medications in slowing the progress or even delaying the onset of AD.
Insights
Inflammation plays a key role in Alzheimer's disease (AD) pathogenesis, potentially causing neurodegeneration and benefiting from anti-inflammatory treatments. This review challenges misconceptions about inflammation's role in AD progression.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Misconceptions regarding inflammation's role in Alzheimer's disease (AD) pathogenesis hinder understanding.
- Inflammation is often viewed as secondary to neurodegeneration or merely clearing debris.
Purpose of the Study:
- To reassess the role of inflammatory mediators in Alzheimer's disease (AD) pathogenesis.
- To challenge the notion that neurodegenerative mechanisms must be primary to be significant.
- To investigate if inflammation is a necessary or sufficient cause of AD neurodegeneration.
Main Methods:
- Review of existing literature on inflammatory molecules and mechanisms in the AD brain.
- Analysis of retrospective and direct clinical trials of anti-inflammatory medications in AD patients.
Main Results:
- Inflammatory molecules and mechanisms are significantly elevated in the AD brain.
- Evidence suggests inflammation may be a necessary component of AD pathogenesis.
- Inflammation may be sufficient to cause neurodegeneration in AD.
- Clinical trials indicate anti-inflammatory drugs may slow AD progression or delay onset.
Conclusions:
- Inflammation is a critical factor in Alzheimer's disease pathogenesis, not just a response to it.
- Targeting inflammatory pathways with anti-inflammatory medications shows therapeutic potential for AD.